IP Library Granted Patent US 9,943,361
Granted Patent B2
US 9,943,361 · App. 15/596,195 · Granted Apr 17, 2018

Treating upper airway nerve tissue

Inventors: Scott J. Wolf (Menlo Park, CA); Andrew Frazier (Sunnyvale, CA)
Assignee: AERIN MEDICAL INC.
A61B18/1485A61B18/02A61B18/082A61B18/1442A61B18/16A61B18/1815A61B18/20A61M25/0084A61M25/10A61N7/022A61B2018/0022A61B2018/00023A61B2018/00327A61B2018/00577A61B2018/00702A61B2018/00821A61B2018/00922A61B2018/0225A61B2018/0293A61B2018/143A61B2018/1425A61B2018/1869A61M2025/0091A61M2025/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,943,361
App. No.
15/596,195
Granted
Apr 17, 2018
Kind
B2
Abstract

Systems and methods for treating a patient's mucus hypersecretion condition are disclosed herein. Certain implementations may involve a method for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough. The method may include advancing a treatment delivery portion of an energy-based treatment device into a nostril of the patient. The treatment delivery portion may contact mucosal tissue of the upper airway without piercing the mucosal tissue. The treatment delivery portion may deliver treatment to at least one tissue selected from the group of the mucosal tissue and another tissue underlying the mucosal tissue to modify a property of the at least one tissue and thus treat at least one of post nasal drip or chronic cough in the patient.

Claims (23)

1. A method for treating an upper airway of a patient by deactivating nerve tissue, the method comprising:

advancing a treatment delivery portion of an energy-based treatment device into a nostril of the patient;

contacting mucosal tissue of the upper airway with the treatment delivery portion, without piercing the mucosal tissue; and

delivering an energy-based treatment from the treatment delivery portion to deactivate nerve tissue underlying the mucosal tissue and thus treat the upper airway.

2. The method of claim 1 , wherein delivering the energy-based treatment to deactivate the nerve tissue comprises ablating the nerve tissue.

3. The method of claim 1 , wherein delivering the energy-based treatment comprises delivering energy in a form selected from the group consisting of ultrasound, microwave, heat, radiofrequency, electrical, light, and laser energy.

4. The method of claim 3 , wherein delivering the energy-based treatment comprises delivering radiofrequency energy from a first electrode on a tissue contact surface of the treatment delivery portion across a convex portion of the tissue contact surface to a second electrode on the tissue contact surface.

5. The method of claim 4 , wherein the first electrode and the second electrode comprise non-piercing bumps on the tissue contact surface, and wherein contacting the mucosal tissue comprises contacting the non-piercing bumps on the tissue contact surface with the mucosal tissue.

6. The method of claim 3 , further comprising:

measuring an amount of delivered energy using a thermocouple on the treatment delivery portion; and

adjusting the amount of delivered energy by adjusting a setting of the treatment delivery portion.

7. The method of claim 1 , wherein delivering the energy-based treatment comprises applying cryotherapy.

8. The method of claim 7 , wherein applying the cryotherapy comprises ablating the nerve tissue.

9. The method of claim 1 , further comprising mechanically altering the mucosal tissue while delivering the energy-based treatment.

10. The method of claim 1 , further comprising determining that the patient has a nasal mucus hypersecretion condition, wherein delivering the energy-based treatment ablates the nerve tissue, thereby ameliorating symptoms of the nasal mucus hypersecretion condition.

11. A method for treating an upper airway to reduce overproduction of nasal mucus, the method comprising:

selecting a patient having nasal mucus overproduction;

advancing a treatment delivery portion of an energy-based treatment device into a nostril of the patient;

contacting mucosal tissue of the upper airway with the treatment delivery portion; and

delivering an energy-based treatment from the treatment delivery portion to nerve tissue underlying the mucosal tissue, wherein delivering the energy-based treatment deactivates the nerve tissue and thereby treats the patient's upper airway to reduce overproduction of mucus.

12. The method of claim 11 , wherein the energy-based treatment is a cryotherapy treatment.

13. The method of claim 11 , wherein delivering the energy-based treatment comprises applying radiofrequency energy.

14. The method of claim 11 , wherein deactivating the nerve tissue comprises ablating the nerve tissue.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2024
From: CRG SERVICING LLC
To: AERIN MEDICAL INC.
Reel/Frame 069654/0467 →
SECURITY INTEREST Recorded Dec 20, 2024
From: AERIN MEDICAL INC.
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 069746/0508 →
SECURITY INTEREST Recorded May 13, 2019
From: AERIN MEDICAL INC.
To: CRG SERVICING LLC
Reel/Frame 049161/0043 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2019
From: WOLF, SCOTT J.; FRAZIER, ANDREW
To: AERIN MEDICAL, INC.
Reel/Frame 048164/0699 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2017
From: WOLF, SCOTT J.; FRAZIER, ANDREW
To: AERIN MEDICAL, INC.,
Reel/Frame 042391/0485 →
Continuity (8)
Continuation 15215762 · Jul 21, 2016
Continuation 14675689 · Mar 31, 2015
Continuation In Part 14319087 · Jun 30, 2014
Continuation In Part 13495844 · Jun 13, 2012
Provisional Application 61974534 · Apr 3, 2014
Provisional Application 61603864 · Feb 27, 2012
Provisional Application 61496930 · Jun 14, 2011
Related Publication 20170245924A1 · Aug 31, 2017